Project Report for Microarray Scanner Business
A microarray scanner project report depends on the business model. A research lab buying one scanner needs equipment finance, while a distributor requires inventory and working capital financing. This guide explains both approaches with real pricing, funding options, and licensing requirements. Get a Completely Custom Bankable Project Report—Rs. 2,999 onwards, delivered in 24-48 hrs, backed by 45,500+ CA-certified reports accepted by SBI, PNB, Bank of Baroda, and all scheduled banks.
Get free Sample
What It Actually Costs
Real market listings tell a clearer story than any industry report. Globally, new microarray scanners are priced anywhere from roughly $20,000 to $150,000 (about ₹17 lakh to over ₹1.25 crore) depending on resolution, laser count, and throughput. In the Indian market specifically, listed prices for systems like the Illumina iScan — one of the most widely used platforms — commonly fall in the ₹10–12 lakh range for the scanner unit itself, with fuller genotyping systems and higher-resolution setups pushing well past that.
Scanner Type | Approx. Price |
Entry Level | ₹10–20 lakh |
Mid Range | ₹20–60 lakh |
High-End Research | ₹60 lakh–₹1.25 crore+ |
You're actually choosing between two different businesses.
This is the part most templates skip entirely. “Microarray scanner” isn’t one business — it’s the same piece of equipment sitting at the center of two very different loan applications:
Buying one for your own lab | Distributing/reselling them | |
What you’re financing | A single high-value equipment purchase | Inventory, showroom/demo unit, and working capital |
Typical loan type | Medical/scientific equipment finance | MSME term loan or trade finance |
Collateral | The scanner itself often qualifies | Inventory and receivables-based |
Who your customers are | You use it in-house for testing/research | Genomics labs, hospitals, research institutions, universities |
Revenue model | Test/service fees from the lab that owns it | Margin on sale, plus AMC/service contracts |
If your report blurs these two together — describing “the microarray scanner business” without saying which one you’re building — a credit officer has no clean way to size the loan or assess the risk correctly.
Buy or Lease? A Real Consideration, Not a Footnote
For labs acquiring a scanner for in-house use, leasing has become a genuinely common alternative to outright purchase — equipment leasing providers specifically serving genomics and life-sciences labs structure 3–5 year terms so a facility can access advanced imaging capability without the full capital outlay upfront. This matters for your project report because a lease-financed acquisition and a purchase-financed one are structured completely differently for a lender, and the “which is cheaper” answer depends on your expected utilization — a core facility running the scanner daily gets better economics from ownership; a smaller lab with occasional need may come out ahead leasing.
If You’re Setting Up the Lab (Not Reselling)
- Udyam (MSME) Registration
- Clinical Establishment registration, if the lab offers diagnostic services to patients rather than pure research use
- Biomedical Waste Management authorization, applicable if handling patient-derived samples
- Qualified technical staff — molecular biology/genomics expertise is non-negotiable; this isn’t equipment a general lab technician can operate without specific training
- Data handling protocols, particularly if the lab processes patient genetic data, given the sensitivity of genomic information
If You’re Distributing or Reselling
- Udyam (MSME) Registration
- GST Registration — essential, given nearly all sales here are B2B to institutions and labs
- Import Export Code (IEC), since most microarray scanners and core components are sourced from international manufacturers (Illumina, Agilent, and similar)
- Authorized dealer/distributor agreement with the manufacturer — lenders view this favorably as it de-risks your supply chain
- Service/AMC capability, since a distributor who can’t support post-sale servicing loses credibility fast in a market this technical
Funding Routes That Fit Each Path
For a lab acquiring a scanner: equipment finance from a bank or NBFC is the standard route, often with the scanner itself serving as partial collateral; larger diagnostic/research setups may combine this with a broader MSME term loan covering facility and staffing costs.
For a distribution business: MUDRA or standard MSME working-capital loans fit smaller operations, while larger distributors dealing in higher-value inventory typically need trade finance or a cash-credit facility to manage the gap between purchasing stock and collecting from institutional buyers, who often pay on extended terms.
CGTMSE-backed collateral-free structuring is relevant to both paths for the MSME-linked portion of financing.
Where the Real Demand Is Coming From
Demand is mainly driven by genomics research laboratories, oncology testing, universities, biotechnology companies, and personalized medicine centers. figure that’s hard to verify at this level of specificity, it’s more useful to name where actual demand growth is concentrated: gene expression profiling, oncology and biomarker research, SNP genotyping, and increasingly, personalized medicine applications where genomic data informs individual treatment decisions.
Academic and research institution core facilities remain a steady buyer base, alongside a growing number of private diagnostic and genomics-testing labs. This is a genuinely specialized, technically-literate customer base — not a volume retail market — and your report’s demand section should reflect that rather than borrowing broad “genomics market is booming” language that doesn’t tell a lender who’s actually going to buy from you.
Where First-Time Applicants Go Wrong
The most common issue isn’t the technology explanation — most reports over-explain how the scanner works and under-explain the business around it. A report heavy on laser/fluorescence mechanics but thin on financing structure, customer base, and service capability reads like a product brochure, not a loan case. The fix is straightforward: cut the technical background to what’s necessary for context, and put the real weight on which of the two business paths above you’re building, who buys from you, and how the numbers work.
Frequently Asked Questions
Yes. Banks and NBFCs provide equipment finance or MSME term loans for eligible laboratories, research centres, and diagnostic facilities, subject to project viability and the lender's approval process.
The investment depends on your business model. A laboratory purchasing a scanner generally requires equipment financing, while a distribution business also needs working capital for inventory, demonstration units, and after-sales support.
Depending on eligibility, entrepreneurs may apply under Mudra Loan, CGTMSE-backed MSME loans, or standard bank equipment finance. The suitable scheme depends on your project size and business type.
A diagnostic laboratory may require Clinical Establishment registration, Biomedical Waste Management authorization, and other state-specific approvals. Research-only laboratories may have different compliance requirements depending on their activities.
Leasing can reduce the initial investment and is suitable for laboratories with limited capital or lower testing volumes. Purchasing is generally more economical for facilities with regular and high equipment utilization.
Yes. Many entrepreneurs operate as authorized distributors or suppliers, earning revenue through equipment sales, installation, annual maintenance contracts (AMC), and technical support.
Basic documents generally include promoter KYC, business registration details, equipment quotations, premises information, estimated project cost, and funding requirements. Additional documents may be required depending on the bank and business model.
Once the required documents and equipment quotations are available, a customized CA-certified project report can generally be prepared within 24–48 hours, depending on the project complexity.